Sign in

    Jialin Jin

    Research Analyst at Morgan Stanley

    Jialin Jin is an Equity Research Associate at Morgan Stanley & Co. LLC, specializing in equity analysis and investment research. He has covered a range of companies within the equity research domain and is noted for his analytical capabilities; however, publicly available records do not specify particular companies or provide quantitative performance metrics. Jin began his research career at Credit Suisse Securities (USA) LLC before joining Morgan Stanley in 2024, developing expertise in financial analysis and market research. He is a FINRA-registered broker and holds relevant securities licenses, reflecting his commitment to regulatory standards in the financial industry.

    Jialin Jin's questions to GoodRx Holdings (GDRX) leadership

    Jialin Jin's questions to GoodRx Holdings (GDRX) leadership • Q4 2024

    Question

    Jialin Jin of Morgan Stanley, on for Craig Hettenbach, asked for more detail on the near-term headwinds reflected in the 2025 guidance, particularly the impact of pharmacy store closures.

    Answer

    CEO Wendy Barnes explained that while it's too early to know the full impact of potential Rite Aid closures, scripts from any closed stores typically migrate to other pharmacies where GoodRx has partnerships. CFO Chris McGinnis confirmed the 2025 guidance accounts for some headwind on monthly active consumers from retail consolidation but expects overall prescription transaction revenue to grow due to a higher revenue-per-script mix.

    Ask Fintool Equity Research AI